Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer

Background Cytochrome P450 CYP1A1 helps detoxify the potential carcinogens in tobacco smoke, it was reported that polymorphisms in the coding gene result in variation in the expression and activity levels which alter metabolism and clearance of carcinogens and therefore modify cancer risk. In this work, we aimed to identify CYP1A1 gene polymorphisms associated with lung cancer in Egyptian population and to examine the interaction effect with Tobacco smoking in modulating disease risk. Methods A case–control study was conducted on 150 unrelated lung cancer patients and 150 unrelated control subjects. Genomic DNA was extracted and sequencing analysis of CYP1A1 gene was performed on ABI PRISM 3100 genetic analyzer. Results Three variants in CYP1A1 gene were identified in heterozygous forms in lung cancer patients I462V, T461N and I286T. A combined variant T461N/ I462V associated with lung cancer and those who carried this variant were 2-times more likely to develop lung cancer (OR = 2.03, 95% CI = 1.81-2.29, P = 0.04), specially the non-small cell type (NSCLC) (OR = 2.20, 95% CI = 1.93–2.50, P = 0.02). Wild type was more frequent among smoker controls (83.3%) compared to smoker lung cancer patients (54.8%), P = 0.03. Association studies to examine the interaction effect of identified variants with Tobacco smoking in modulating disease risk showed no significant associations. Identified polymorphisms showed no significant implication on the stage or the prognosis of the disease. Conclusion Our findings support that CYP1A1 polymorphisms play a role in the pathogenesis of lung cancer. In Egyptian population, CYP1A1 I462V, T461N and I286T variants were identified among lung cancer patients and combined T461N/ I462V was a risk variant for NSCLC in non smokers.


Background
Lung cancer progression is characterized by cumulative alterations in key molecules involved in the cell cycle, signaling and angiogenesis pathways. Most lung cancer patients demonstrate chromosomal abnormalities at the site of tumor suppressor genes or have mutations in known oncogenes [1].
In the laboratory, chemicals in tobacco reduce the capacity to repair DNA damage in cells from lung cancer patients than cells from normal individuals [2]. As many smokers do not develop lung cancer, it is likely that inherited factors influence the effects of tobacco. There is a considerable interest in variants of genes that help detoxify the carcinogens in tobacco smoke, such as members of the cytochrome P450 (CYP), glutathione S-transferase (GST) and N-acetyltransferase (NAT) gene families [3].
Scientists have identified 57 human CYP genes and 33 pseudo genes divided into 18 families and 42 subfamilies. Now CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 and other gene polymorphisms have been confirmed and specific metabolic enzyme phenotypes differ with regions and races [4]. CYP gene changes can cause increased activity of the enzyme, decreased activity or even inactivity. In addition, mutations at the substrate recognition sites may lead to changes in enzyme specificity [5].
CYP1A1 plays a major role as a carcinogen activating enzyme within the CYP system. Unlike most CYP enzymes, CYP1A1 expression is mainly found in extra hepatic tissues, including the lung, where it metabolizes and is markedly induced by polycyclic aromatic hydrocarbons (PAHs) [6]. Elevated CYP1A1 inducibility is associated with pulmonary PAH-related DNA adduction [7] and high lung cancer risk [8]. Both CYP1A1 expression and the formation of these PAH-DNA adducts in human lung tissue are highly variable [9][10][11], possibly due to differing exposure to environmental factors and to genetic polymorphisms affecting the CYP1A1 gene locus [12].
The first variant allele identified was CYP1A1*2A (MspI or m1 polymorphism) and is found in 5% of Caucasians [13]. CYP1A1*2C (Ile462Val or m2 polymorphism) is rare in Caucasians and is usually detected with CYP1A1*2A [14]. The combination of both variants is referred to as CYP1A1*2B. CYP1A1*3, consisting of a T3205C base change (m3), seems to show enhanced enzyme activity, although it is extremely uncommon in Caucasians [13]. Finally, CYP1A1*4, a Thr461Asn (m4) amino acid change, detected in Caucasians with a frequency of roughly 3%, has also been related to greater enzyme catalytic efficiency [15]. These CYP1A1 polymorphisms have been extensively studied with regard to risk of lung cancer. However, whereas some studies report increased risk in the presence of some of the mutations [16,17], there are many other contradictory results due to ethnic differences [18,19].
The aim of this work is to identify CYP1A1 gene polymorphisms associated with lung cancer in Egyptian population and to examine the interaction effect with Tobacco smoking in modulating disease risk.

Subjects
This work was collaboration between National Cancer Institute (NCI) and National Research Center (NRC), Cairo, Egypt. A case-control study was conducted on 150 unrelated adult patients with primary lung cancer and 150 unrelated controls. Patients were presented to NCI from different governorates of Egypt; Cairo, Giza, Qalyubia, Sharqia, Monufia, Kafr El-Sheikh, Minya, Faiyum, Asyut, Sohag and Qena. All subjects included in the study were interviewed to fill a medical questionnaire with special consideration to the lifetime history of tobacco use, residence, occupational history and family history of cancer. Thorough  clinical examination and chest radiography were applied. Blood sample was obtained from each subject for sequencing analysis of the human CYP1A1 gene. Sample for histopathology examination of cancer was obtained from each patient either by open biopsy or via bronchoscopy. The exclusion criteria included previous history of cancer, metastasized cancer from other organs, patients with pulmonary fibrosis, acute interstitial pneumonia and previous radiotherapy or chemotherapy or receiving any anti-cancer treatment before enrollment in the study. The study was approved by the ethics committee of the National Research Center. All subjects were aware by the nature of the study and gave a written informed consent.

DNA extraction
Genomic DNA was extracted from blood samples obtained from 150 controls and 150 lung cancer patients using QIAamp DNA extraction kit (Qiagen Hilden, Germany, Cat no. 51304) according to the manufacturer's instructions.

Sequence analysis of the CYP1A1 gene
The sequence of the human CYP1A1 gene described in the GenBank (accession number X02612) was used as a reference. The primers used for the amplification and the direct sequencing of all seven exons and exon-intron junctions of the gene are shown in Table 1. PCR for each fragment of CYP1A1 gene was conducted in a 25 μl reaction mixture containing 100 ng of genomic DNA, 20 pmol of each primer and 12.5 μl of AmpliTaq Gold 360 Master Mix (Applied BioSystems, Foster City, CA, USA). PCR cycling conditions consisted of initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 30s, annealing at 60°C for 30s and extension at 72°C for 30s, followed by a final extension of 5 min at 72°C. PCR products were checked first on 2% agarose gel for successful amplification ( Fig. 1) and was further purified using PureLink Quick PCR Purification Kit (Invitrogen, Germany). The purified PCR products were directly sequenced in both directions using the Big Dye Termination kit (Applied Biosystems, Foster City, CA, USA) and sequences were determined using ABI PRISM 3100 genetic analyzer (Applied Biosystems).

Statistical analysis
Data were analyzed using SPSS version 18.0 (Chicago, IL, USA). Data were expressed as number and percentage of total for categorical variables. Chi-square test (χ 2 ) was used to compare the distribution of CYP1A1 genotypes between groups. Likelihood ratio was used when the expected count was less than 5 in more than 20% of the cells. The associations between genotype and risk of lung cancer were estimated by odds ratio (OR) and 95% confidence interval (95% CI) using logistic regression models. The ORs were adjusted for age, smoking status, and packyears. P-value <0.05 was considered significant.

Results
The study included 300 subjects; 150 unrelated lung cancer patients and 150 unrelated control subjects. A statistical significant age difference was found between controls (mean 43.3 ± 11.1 years) and patients (mean 56.7 ± 9.79 years) (p < 0.001), denoting that older age is associated with higher risk of lung cancer. There was a statistical significant difference in gender between the two groups with 51.3% females and 48.7% males in control group vs. 24% females and 76% males in patients group (X 2 = 25.82, P < 0.0001), with 3.5-times increased risk to develop lung cancer in males than in females (OR = 3.49, CI: 2.13-5.69). Mean pack-years was significantly higher in patients (21.4 ± 2.25) than in controls (4.0 ± 0.77). Smoking habit was significantly higher among patients (X 2 = 56.88, P < 0.0001), with an odd ration of 6.69 (CI: 3.99-11.20) denoting a higher risk to develop lung cancer in smokers by 6.7 times the non-smokers.
There was statistical significant difference in the distribution of CYP1A1 variants in relation to smoking habit among lung cancer patients and control subjects. The wild type gene was the most frequent among smoker controls compared to non-smoker controls and lung cancer patients (P = 0.03) ( Table 3). Association studies of CYP1A1 polymorphisms and smoking with susceptibility to lung cancer showed no significant association with disease risk (Table 4). No significant association of CYP1A1 polymorphisms and pack year with susceptibility to lung cancer (Table 5). Identified polymorphisms showed no significant implication on the stage or the prognosis of the disease (Tables 6 and 7).

Discussion
CYP1A1 is a polymorphic gene located at 15q24.1 with 7 exons and 6 introns. In addition to the wild-type (CYP1A1*1), 10 variant alleles have been identified [7]. Variants CYP1A1*2A, CYP1A1*2C, CYP1A1*3 and CYP1A1*4 with trivial names m1, m2, m3 and m4; respectively were the most commonly studied for cancer link [20,21]. About 90% of lung cancer is strongly associated with Tobacco smoking [22]. Our results showed an estimated risk for lung cancer 6.7 times greater in Egyptian smokers than in non-smokers compared to 2.61 times in a previous study [23] and an increased risk to develop lung cancer in males by 3.5-times than in females, which might be attributed to the higher incidence of smoking habit among males.
In our patients, three polymorphisms in CYP1A1 gene were identified; CYP1A1*2C (I462V) was detected in 12.7% of control subjects and 11.4% of patients, and CYP1A1*4 (T461N) identified in 22% of controls and 30.9% of patients. In one non-smoker adenocarcinoma patient, the rare CYP1A1 857 T > C (I286T) was identified. Ethnic difference in the distribution of CYP1A1*2C variant has been demonstrated in lung cancer patients, while few reports are available for CYP1A1*4. Frequencies of CYP1A1*2C ranged from 2.2% to 8.9% in Caucasians and was about 19.8% in Japanese, while CYP1A1*4 allele was found in 2% to 5.7% of a Caucasian population [24][25][26][27]. Asian reports rarely observed presence of CYP1A1*4 variant [21,28,29], meanwhile, it was more common among whites [30] and it was reported, by itself, as a lung cancer risk factor in Caucasians [12].
CYP1A1*2C and *4 variants have generally been associated with moderate to high risk of lung cancer [21]. These variants are rare in Caucasians and African-Americans. While studies of African-Americans have reported predominantly negative findings [31,32], studies of Caucasians have been mixed [33,34]. Although I462V polymorphism is relatively frequent in Asian populations (18% to 25%), the Val allele is rare in Caucasian control populations, occurring in 7% to 13% of people [35][36][37] which agreed with obtained results in our control population (12.7%).
In the studied Egyptian population, combined variant T461N/ I462V (m2/m4) was found in 2.7% of lung cancer patients associated with 2-times higher risk to develop lung cancer compared to either control or individual m2 or m4 variant carriers.
In an Australian study to identify lung cancer-risk modifying CYP1A1 haplotypes, *2A and *2C variants were significantly over-represented in NSCLC cases compared to controls, whereas *4 variant was underrepresented. CYP1A1 haplotypes (in allele order CYP1A1*4, *2C, *2A); CGC and CG associated with increased risk of lung cancer confirming CYP1A1 polymorphisms as minor risk factor for NSCLC. It was reported that CYP1A1*2C increase the overall risk of    [21]. In our study, no significant difference of lung cancer risk for variant alleles between different pathological subtypes of NSCLC. We could not demonstrate a role of CYP1A1on the stage or the prognosis of the disease, in agreement with a previous study in Taiwan [40]. Controversial results were obtained from previous studies on interaction of smoking and CYP1A1 variants. In the present study CYP1A1*1, wild type, was statistically more frequent among smoker controls. There was no association demonstrated between the heterozygous alleles of CYP1A1 variants, smoking or smoking heaviness in prediction of lung cancer, 75% (3 of 4) of CYP1A1 combined variant (T461N/ I462V) carriers were non-smokers.
Smoking was identified as a predominant risk factor and CYP1A1*2A polymorphism significantly associated with increased lung cancer risk (OR = 1.69; 95% CI = 1.11-2.59, p = 0.01), whereas CYP1A1*2A and *2C and Ile105Val imparted increased risk in non-smokers only [41]. Though, Wenzlaff et al. found no significant association with any of CYP1A1 variants in never smokers [42], a recent pooled analysis by Hung et al. reported more than 2-fold increase in lung cancer susceptibility for both CYP1A1*2B and *2C variants among non-smoker Caucasians [39]. According to Song et al., non-smokers with CYP1A1*2A variant had elevated risk than those homozygous for wild type alleles [21]. Previous study in life-time nonsmoking Chinese women reported an elevated risk of lung cancer for both CYP1A1*2B and *2C homozygous genotypes, furthermore, lung cancer risk associated with both polymorphisms was higher in women with lower environmental tobacco smoke exposure [43]. I462V polymorphism is not related to lung cancer overall, but it might play a role at lower levels of Tobacco smoking among subjects with impaired carcinogen detoxification [44].

Conclusion
Beside the wild type CYP1A1*1, three variants of CYP1A1 gene were identified in Egyptian population; CYP1A1*2C, CYP1A1*4 and the rare CYP1A1 c.857 T > C (I286T). Combined variant CYP1A1*2C/ CYP1A1*4 associated with higher risk of lung cancer specially NSCLC among non-smokers. Identification of these variants may help in risk assessment, early detection and improvement of current treatment options for lung cancer patients. Further studies to clarify the role of these variants in the pathogenesis of the disease are needed.